← Leaderboards
Stephen Alan Sands
Albert Einstein College Of Medicine, Inc
$2,398,606
Attributed
$4,296,189
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $695.4K · FY2015–24$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,296,189 · 3
By mechanism
R01$3,884,129 · 2
R21$412,060 · 1
Top collaborators
- Peter D. Cole7 shared
Others in their field
Top investigators on “Protocols Documentation”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Jeffrey P Krischer · University Of South Florida$562,015,656
- Lawrence Corey · Fred Hutchinson Cancer Center$498,533,651
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Judith S. Currier · University Of California Los Angeles$445,196,577
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$381,639,813
Research focus
Protocols DocumentationBiological MarkersChildhood LeukemiaQuality Of LifeBrainNeurocognitiveNeurocognitive DeficitSurvivorsChildFoundationsCognitive DeficitsClinical TrialsFolic AcidCognitive FunctionComputersFunctional DisorderDana-Farber Cancer InstituteBehavior TherapyCerebrospinal FluidDeteriorationFundingAftercareBaseCancer Therapy
Grant awards (9)
Prospective international phase-III study to improve neurocognitive outcomes in young children with low-risk medulloblastoma (YCMB-LR)$235,324
R01 · FY2024 · CA · contact PI
Prospective international phase-III study to improve neurocognitive outcomes in young children with low-risk medulloblastoma (YCMB-LR)$265,699
R01 · FY2023 · CA · contact PI
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL$666,287
R01 · FY2022 · CA
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL$682,392
R01 · FY2021 · CA
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL$679,885
R01 · FY2020 · CA
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL$659,113
R01 · FY2019 · CA
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL$695,429
R01 · FY2018 · CA
Markers of Cognitive Decline During Treatment for Childhood ALL$215,938
R21 · FY2016 · CA
Markers of Cognitive Decline During Treatment for Childhood ALL$196,122
R21 · FY2015 · CA